Redx Pharma
Alderley Edge, United Kingdom

Redx Pharma specialises in the discovery and early clinical development of small molecule therapeutics, with an emphasis on oncology and fibrotic disease. The two lead compounds will be progressed through proof-of-concept studies and then partnered for further development. Existing earlier-stage collaboration partners include AstraZeneca and Jazz Pharmaceuticals.

Investment Perspective

Redx Pharma is a UK-based clinical stage drug discovery company that specialises in developing highly specific small molecules based on its proven medicinal chemistry expertise and research platform. These are either “best-in-class” or “first-in-class” and target existing unmet needs in large oncology and fibrosis indications. A driven management team is implementing a focussed and ambitious strategy that should be transformative for the business over the medium term. The approach has been validated by a series of out-licensing and partnering deals. Knowledgeable and supportive shareholders have rebuilt the balance sheet, but further funding is, in our view, required to capitalise on the existing opportunities. Our valuation, based on conservative assumptions, is £296m, equivalent to 152p/share, and 92p fully diluted.

Market information

SymbolPrimary exchanges


£25.5m placing extends runway to end-2022
Lighthouse | 02 Dec 2020
Proof is in the pipeline
Initiation | 14 Sep 2020

Recent News

£25.5m placing and open offer
02 Dec 2020
Appointment of Chief Medical Officer
27 Oct 2020
New research collaboration with Jazz Pharmaceuticals
09 Sep 2020
Out licensing agreement with AstraZeneca
04 Aug 2020